Catalent completes Juniper merger to ‘expand and strengthen’ oral dose manufacturing

By Flora Southey contact

- Last updated on GMT

(Image: Getty/sesame)
(Image: Getty/sesame)

Related tags: Catalent pharma solutions, Juniper pharmaceuticals

Juniper Pharmaceuticals will become a wholly owned subsidiary of Catalent Pharma Solutions today, says the CDMO.

Catalent announced the successful completion of its tender offer in a US Securities and Exchange Commission (SEC) filing​ this morning. The contract development and manufacturing organisation (CDMO) paid approximately $130m in cash for Juniper’s stock, priced at $11.50 per share.

“The acquisition of Juniper expands and strengthens Catalent’s offerings in formulation development, bioavailability solutions and clinical-scale oral dose manufacturing, and complements its integrated global clinical and commercial supply network,” ​said Catalent in the filing.

“In addition, as a result of the merger, Juniper will become a wholly owned subsidiary of [Catalent] and the shares of common stock of Juniper will cease to be traded on the NASDAQ Global Select Market,” ​the firm added.

Catalent announced plans​ to acquire Juniper mid-2018, which it said would provide a new European hub and attract a larger share of early-phase development business. The CDMO will also incorporate Juniper’s Nottingham, UK-based Pharma Services business into its network.

As Juniper’s parent company, Catalent will continue to supply Crinone (progesterone gel), marketed by Merck KGaA outside the US.

The merger marks Catalent’s latest investment in development and manufacturing services. In 2016​, the CDMO acquired Pharmatek Laboratories in San Diego, US, and in 2017, acquired Cook Pharmica​ to expand its biologics, cell culture manufacturing, and packaging capabilities.

Earlier this year, the announced plans to invest in its Somerset, NJ, facility, and build a centre of excellent on America’s East Coast.

In April 2018​, Catalent increased its clinical packaging and storage capacity in Philadelphia, PA, with a $5.5m site expansion.

Related news

Show more

Related products

show more

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us

Products

View more

Webinars